Sorafenib has been used as maintenance therapy post allogeneic SCT in FLT3-mutated AML in single arm and randomized trials, all showing survival and/or RFS benefits for the addition of sorafenib maintenance123,124. The gene discussed is FLT3; the disease is acute myeloid leukemia.